Verana Health, a digital health company has announced the launch of a Urology Qdata module to help support clinical research surrounding non-muscle invasive bladder cancer (NMIBC). This highly curated module will help facilitate a more comprehensive view of the NMIBC patient journey including disease progression over time.
Exclusive insights into more than 50,000 de-identified patients with NMIBC are derived from key variables extracted from unstructured clinician notes including diagnosis date, treatments, recurrences, documented T stage, and tumor grade for risk determination. These exclusive therapeutic insights can be used to help better understand treatment patterns and outcomes to inform therapeutic strategies for patients with this disease.
Qdata NMIBC is powered by the American Urological Association's (AUA) Quality Registry (AQUA), the world's largest real-world clinical data registry for urology. The AQUA Registry includes eight years of longitudinal data from more than 2,100 healthcare providers representing more than 75 million de-identified patient encounters from nearly 10 million de-identified patients. Verana Health has an exclusive partnership with the AUA to de-identify, curate, and analyze electronic health record (EHR) data from the AQUA Registry.
Verana Health's Qdata NMIBC has the potential to provide the missing information to help clinicians and researchers track disease progression and measure outcomes for bladder cancer patients before it progresses to muscle invasive or metastatic disease. This new module comprises quality data from structured and unstructured fields that document real-world diagnosis, treatments, and outcomes and is likely to reflect earlier-stage data than found in claims or electronic health records from oncologists.
The new module will benefit life sciences companies, and ultimately patients, by helping to:
Identify practices treating patients with specific NMIBC profiles to better inform trial design and efficiency.
Enable better visibility into the patient journey and disease progression for patients with NMIBC stratified by stage, grade and treatments for HEOR and medical affairs.
"Qdata NMIBC can help provide the high-quality RWD needed for life sciences research and the development and utilization of drugs to more effectively treat this disease at its earlier stages," said Sujay Jadhav, CEO of Verana Health. "AUA and Verana Health are helping to better enable NMIBC researchers to gain greater insights into the progression of this disease and how it can be most effectively treated to reduce recurrences. The result will be to help improve patient and population outcomes and reduce healthcare utilization."
Join the HealthXL Meeting on ‘Standards for Robust Evidence from Digital Health in Oncology’ on 21st February. Click here to Request to Join.
Click here to read the original news story.